Abstract:The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of oncologists and translational scientists, driven by exciting results with KRAS-targeted therapies for non-small cell lung cancer (NSCLC) patients. While KRAS mutations continue to drive high cancer diagnosis and death, researchers have developed unique strategies to target KRAS variations. Having been investigated over the past 40 years and considered "undruggable" due to the lack of pharmacological binding pockets, recent breakthroughs and accelerated FDA approval of the first covalent inhibitors targeting KRAS G12C , have largely sparked further drug development. Small molecule development has targeted the previously identified primary location alterations such as G12, G13, Q61, and expanded to address the emerging secondary mutations and acquired resistance. Of interest, the non-covalent KRAS G12D targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside. While this manuscript was under review a novel class of first covalent inhibitors specific for G12D was published, These so-called malolactones can crosslink both GDP and GTP bound forms of G12D. Inhibition of the latter state suppressed downstream signaling and cancer cell proliferation in vitro and in mouse xenografts. Moreover, a non-covalent pan-KRAS inhibitor, BI-2865, reduced tumor proliferation in cell lines and mouse models. Finally, the next generation of KRAS mutant-specific and pan-RAS tri-complex inhibitors have revolutionized RAS drug discovery. This review will give a structural biology perspective on the current generation of KRAS inhibitors through the lens of emerging secondary mutations and acquired resistance.

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Targeting KRAS in cancer

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

KRAS mutation: from undruggable to druggable in cancer

Drugging KRAS: current perspectives and state-of-art review

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting cancer with small molecule pan-KRAS degraders

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Targeting KRAS in Colorectal Cancer

Eliminating oncogenic RAS: back to the future at the drawing board

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

KRAS, a New Target for Precision Medicine in Colorectal Cancer?

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms

Targeting KRAS in pancreatic cancer

Targeting KRAS in Non-Small Cell Lung Cancer

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance